Actively Recruiting
Evaluating Oral Tovorafenib DAY101 for Treatment of Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis in Children and Young Adults
Led by National Cancer Institute (NCI) · Updated on 2026-10-30
48
Participants Needed
123
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety, side effects, optimal dose, and effectiveness of tovorafenib DAY101 in treating children and young adults with progressive, relapsed, or refractory Langerhans cell histiocytosis LCH. LCH is a condition where too many immature white blood cells called Langerhans cells build up and form tumors that can damage bones, skin, lungs, and the pituitary gland. This disease occurs more often in children and young adults, and the study focuses on those with relapsed or refractory LCH, including those with specific genetic mutations. Participants receive tovorafenib orally once a week on days 1, 8, 15, and 22 of each 28-day cycle. Treatment continues for up to 12 cycles unless the disease worsens or side effects become unacceptable. During the study, participants undergo various scans such as echocardiography ECHO or multigated acquisition MUGA, and imaging with FDG-PET or CT to monitor the disease. Blood and urine samples are collected regularly. If bone marrow or central nervous system involvement is suspected, participants may also have bone marrow biopsies and lumbar punctures. Throughout the trial, researchers assess response to treatment, side effects, event-free survival, and overall survival up to two years. After treatment, participants are followed up at 28 days, then at 3, 6, 9, and 12 months, and again at two years post-treatment. The study includes monitoring of bone marrow and blood for genetic mutations and disease markers. This comprehensive approach helps evaluate tovorafenibs impact on relapsed or refractory LCH over time.
CONDITIONS
Brief Title
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here